Inhibition of the mechanistic target of rapamycin (mTOR)–Rapamycin and beyond

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 5, 2016, Pages

  Lamming, Dudley W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; IMMUNOSUPPRESSIVE AGENT; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CAENORHABDITIS ELEGANS; CANCER INHIBITION; CELL AGING; DIPTERA; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; LIFESPAN; LONGEVITY; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN QUALITY; SIGNAL TRANSDUCTION; STEM CELL; WORM; ANIMAL; DRUG EFFECTS; METABOLISM; MOUSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGEVITY; MICE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84964995198     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025924     Document Type: Article

References (114)

1. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV. 2011. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10: 4230–4236.
2. Anthony TG, Morrison CD, Gettys TW. 2013. Remodeling of lipid metabolism by dietary restriction of essential amino acids. Diabetes 62: 2635–2644.
3. Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, Pumper CP, Kimple ME, Lamming DW. 2016. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell 15: 28–38.
4. Bar-Peled L, Sabatini DM. 2014. Regulation of mTORC1 by amino acids. Trends Cell Biol 24: 400–406.
5. Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, Spear ED, Carter SL, Meyerson M, Sabatini DM. 2013. Atumor suppressorcomplex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340: 1100–1106.
6. Betz C, Stracka D, Prescianotto-Baschong C, Frieden M, Demaurex N, Hall MN. 2013. Feature article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc Natl Acad Sci 110: 12526–12534.
7. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L. 2010. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 11: 35–46.
8. Blomstrand E, Eliasson J, Karlsson HK, Kohnke R. 2006. Branched-chain amino acids activate key enzymes in protein synthesis after physical exercise. J Nutr 136: 269S–273S.
9. Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning BD, Horng T. 2013. The TSC-mTOR pathway regulates macrophage polarization. Nat Commun 4: 2834.
10. Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS. 2011. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson–Gilford progeria syndrome cells. Sci Transl Med 3: 89ra58.
11. Caron A, Richard D, Laplante M. 2015. The roles of mTOR complexes in lipid metabolism. Annu Rev Nutr 35: 321–348.
12. Chantranupong L, Wolfson RL, Orozco JM, Saxton RA, Scaria SM, Bar-Peled L, Spooner E, Isasa M, Gygi SP, Sabatini DM. 2014. The sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1. Cell Rep 9: 1–8.
13. Check Hayden E. 2014. Pet dogs set to test anti-ageing drug. Nature 514: 546.
14. Chen C, Liu Y, Liu Y, Zheng P. 2009. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2: ra75.
15. Cuervo AM, Bergamini E, Brunk UT, Droge W, Ffrench M, Terman A. 2005. Autophagy and aging: The importance of maintaining “clean” cells. Autophagy 1: 131–140.
16. Dai DF, Karunadharma PP, Chiao YA, Basisty N, Crispin D, Hsieh EJ, Chen T, Gu H, Djukovic D, Raftery D, et al. 2014. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell 13: 529–539.
17. Drake JC, Peelor FF III, Biela LM, Watkins MK, Miller RA, Hamilton KL, Miller BF. 2013. Assessment of mitochondrial biogenesis and mTORC1 signaling during chronic rapamycin feeding in male and female mice. J Gerontol A Biol Sci Med Sci 68: 1493–1501.
18. Fok WC, Bokov A, Gelfond J, Yu Z, Zhang Y, Doderer M, Chen Y, Javors M, Wood WH III, Zhang Y, et al. 2014a. Combined treatment of rapamycin and dietary restriction has a larger effect on the transcriptome and metabolome of liver. Aging Cell 13: 311–319.
19. Fok WC, Chen Y, Bokov A, Zhang Y, Salmon AB, Diaz V, Javors M, Wood WH III, Zhang Y, Becker KG, et al. 2014b. Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PLoS ONE 9: e83988.
20. Fontana L, Partridge L. 2015. Promoting health and longevity through diet: From model organisms to humans. Cell 161: 106–118.
21. Gan X, Wang J, Wang C, Sommer E, Kozasa T, Srinivasula S, Alessi D, Offermanns S, Simon MI, Wu D. 2012. PRR5L degradation promotes mTORC2-mediated PKC-d phosphorylation and cell migration downstream of Ga12. Nat Cell Biol 14: 686–696.
22. Garcia-Martinez JM, Alessi DR. 2008. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416: 375–385.
23. Garelick MG, Mackay VL, Yanagida A, Academia EC, Schreiber KH, Ladiges WC, Kennedy BK. 2013. Chronic rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo. Cell Cycle 12: 2493–2504.
24. Gharibi B, Farzadi S, Ghuman M, Hughes FJ. 2014. Inhibition of Akt/mTOR attenuates age-related changes in mesenchymal stem cells. Stem Cells 32: 2256–2266.
25. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM. 2014. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 4: 554–563.
26. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC-α, but not S6K1. Dev Cell 11: 859–871.
27. Han X, Turdi S, Hu N, Guo R, Zhang Y, Ren J. 2012. Influence of long-term caloric restriction on myocardial and cardiomyocyte contractile function and autophagy in mice. J Nutr Biochem 23: 1592–1599.
28. Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C. 2007. Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell 6: 95–110.
29. Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon C. 2008. A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet 4: e24.
30. Harputlugil E, Hine C, Vargas D, Robertson L, Manning BD, Mitchell JR. 2014. The TSC complex is required for the benefits of dietary protein restriction on stress resistance in vivo. Cell Rep 8: 1160–1170.
31. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, et al. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460: 392–395.
32. Harrison DE, Strong R, Allison DB, Ames BN, Astle CM, Atamna H, Fernandez E, Flurkey K, Javors MA, Nadon NL, et al. 2014. Acarbose, 17-α-estradiol, and nordihy-droguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell 13: 273–282.
33. + cells. J Exp Med 205: 565–574.
34. Hernandez-Negrete I, Carretero-Ortega J, Rosenfeldt H, Hernandez-Garcia R, Calderon-Salinas JV, Reyes-Cruz G, Gutkind JS, Vazquez-Prado J. 2007. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J Biol Chem 282: 23708–23715.
35. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y. 2003. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421: 182–187.
36. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, et al. 2011. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332: 1317–1322.
37. Huang J, Dibble CC, Matsuzaki M, Manning BD. 2008. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 28: 4104–4115.
38. Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, Gutkind JS. 2012. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell 11: 401–414.
39. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. 2008. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. Embo J 27: 1919–1931.
40. Johnston O, Rose CL, Webster AC, Gill JS. 2008. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19: 1411–1418.
41. Kaeberlein M, Powers RW III, Steffen KK, Westman EA, Hu D, Dang N, Kerr EO, Kirkland KT, Fields S, Kennedy BK. 2005. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 310: 1193–1196.
42. Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, Gray NS, Turk BE, Yaffe MB, Sabatini DM. 2013. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341: 1236566.
43. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. 2004. Regulation of lifespan in Drosophila by modulation of genes in the TORsignaling pathway. Curr Biol 14: 885–890.
44. Khanna N, Fang Y, Yoon MS, Chen J. 2013. XPLN is an endogenous inhibitor of mTORC2. Proc Natl Acad Sci 110: 15979–15984.
45. Kim J, Kundu M, Viollet B, Guan KL. 2011. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13: 132–141.
46. Kim SJ, DeStefano MA, Oh WJ, Wu CC, Vega-Cotto NM, Finlan M, Liu D, Su B, Jacinto E. 2012. mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8. Mol Cell 48: 875–887.
47. Kruegel U, Robison B, Dange T, Kahlert G, Delaney JR, Kotireddy S, Tsuchiya M, Tsuchiyama S, Murakami CJ, Schleit J, et al. 2011. Elevated proteasome capacity extends replicative lifespan in Saccharomyces cerevisiae. PLoS Genet 7: e1002253.
48. Kume S, Uzu T, Horiike K, Chin-Kanasaki M, Isshiki K, Araki S, Sugimoto T, Haneda M, Kashiwagi A, Koya D. 2010. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 120: 1043–1055.
49. Lamming DW, Anderson RM. 2014. Metabolic effects of caloric restriction. In eLS. Wiley, Chichester, NY.
50. Lamming DW, Medvedik O, Kim KD, Sinclair DA. 2007. Calorie restriction and TOR signaling converge on sirtuin-mediated lifespan extension in Saccharomyces cerevisiae. Age 29: 118–118.
51. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, et al. 2012. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335: 1638–1643.
52. Lamming DW, Ye L, Sabatini DM, Baur JA. 2013. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 123: 980–989.
53. Lamming DW, Demirkan G, Boylan JM, Mihaylova MM, Peng T, Ferreira J, Neretti N, Salomon A, Sabatini DM, Gruppuso PA. 2014a. Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2). FASEB J 28: 300–315.
54. Lamming DW, Mihaylova MM, Katajisto P, Baar EL, Yilmaz OH, Hutchins A, Gultekin Y, Gaither R, Sabatini DM. 2014b. Depletion of rictor, an essential protein component of mTORC2, decreases male lifespan. Aging Cell 13: 911–917.
55. Lamming DW, Cummings NE, Rastelli AL, Gao F, Cava E, Bertozzi B, Spelta F, Pili R, Fontana L. 2015. Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model. Oncotarget 6: 31233–31240.
56. Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, Fontana L, Mirisola MG, Guevara-Aguirre J, Wan J, et al. 2014. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab 19: 407–417.
57. Li X, Gao T. 2014. mTORC2 phosphorylates protein kinase Cto regulate its stability and activity. EMBORep 15: 191–198.
58. Li F, Yin Y, Tan B, Kong X, Wu G. 2011. Leucine nutrition in animals and humans:mTOR signaling and beyond. Amino Acids 41: 1185–1193.
59. Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, et al. 2012. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J Biol Chem 287: 9742–9752.
60. Liu P, Wang Z, Wei W. 2014a. Phosphorylation of Akt at the C-terminal tail triggers Akt activation. Cell Cycle 13: 2162–2164.
61. Liu Y, Diaz V, Fernandez E, Strong R, Ye L, Baur JA, Lamming DW, Richardson A, Salmon AB. 2014b. Rapamycin-induced metabolic defects are reversible in both lean and obese mice. Aging (Albany NY) 6: 742–754.
62. Long X, Ortiz-Vega S, Lin Y, Avruch J. 2005. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 280: 23433–23436.
63. Mahe E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF, Mamzer-Bruneel MF, de Prost Y, Kreis H, Bodemer C. 2005. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79: 476–482.
64. Maier E, Duschl A, Horejs-Hoeck J. 2012. STAT6-dependent and-independent mechanisms in Th2 polarization. Eur J Immunol 42: 2827–2833.
65. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S. 2012. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1b and enhancing NMDA signaling. Aging Cell 11: 326–335.
66. McCarty MF, Barroso-Aranda J, Contreras F. 2009. The lowmethionine content of vegan diets may make methionine restriction feasible as a life extension strategy. Med Hypotheses 72: 125–128.
67. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al. 2011. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364: 1595–1606.
68. Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, Manning BD. 2014. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156: 771–785.
69. Mieulet V, Roceri M, Espeillac C, Sotiropoulos A, Ohanna M, Oorschot V, Klumperman J, Sandri M, Pende M. 2007. S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover. Am J Physiol Cell Physiol 293: C712–C722.
70. Miller RA, Harrison DE, Astle CM, Baur JA, Rodriguez Boyd A, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, et al. 2011a. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66A: 191–201.
71. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, et al. 2011b. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66: 191–201.
72. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, et al. 2014. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13: 468–477.
73. Mizunuma M, Neumann-Haefelin E, Moroz N, Li Y, Blackwell TK. 2014. mTORC2-SGK-1 acts in two environmentally responsive pathways with opposing effects on longevity. Aging Cell 13: 869–878.
74. Moberg M, Apro W, Ohlsson I, Ponten M, Villanueva A, Ekblom B, Blomstrand E. 2014. Absence of leucine in an essential amino acid supplement reduces activation of mTORC1 signalling following resistance exercise in young females. Appl Physiol Nutr Metab 39: 183–194.
75. Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schroder S, Adler T, Afonso LC, Aguilar-Pimentel JA, Becker L, Garrett L, et al. 2013. Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest 123: 3272–3291.
76. Nojima A, Yamashita M, Yoshida Y, Shimizu I, Ichimiya H, Kamimura N, Kobayashi Y, Ohta S, Ishii N, Minamino T. 2013. Haploinsufficiency of akt1 prolongs the lifespan of mice. PLoS ONE 8: e69178.
77. O’Leary MN, Schreiber KH, Zhang Y, Duc AC, Rao S, Hale JS, Academia EC, Shah SR, Morton JF, Holstein CA, et al. 2013. The ribosomal protein Rpl22 controls ribosome composition by directly repressing expression of its own paralog, Rpl22l1. PLoS Genet 9: e1003708.
78. Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN, Blagosklonny MV. 2014. Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Cancer Biol Therapy 15: 586–592.
79. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. 2012. Regulation of immune responses by mTOR. Annu Rev Immunol 30: 39–68.
80. Powers RW III, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. 2006. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev 20: 174–184.
81. Pusceddu S, Tessari A, Testa I, Procopio G. 2014. Everolimus in advanced solid tumors: When to start, early or late? Tumori 100: 2e–3e.
82. Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, MacKay VL, An EH, Strong R, Ladiges WC, et al. 2012. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med 4: 144ra103.
83. Robida-Stubbs S, Glover-Cutter K, Lamming DW, Mizunuma M, Narasimhan SD, Neumann-Haefelin E, Sabatini DM, Blackwell TK. 2012. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell Metab 15: 713–724.
84. Rodriguez KA, Edrey YH, Osmulski P, Gaczynska M, Buffenstein R. 2012. Altered composition of liver proteasome assemblies contributes to enhanced proteasome activity in the exceptionally long-lived naked mole-rat. PLoS ONE 7: e35890.
85. Rodriguez KA, Dodds SG, Strong R, Galvan V, Sharp ZD, Buffenstein R. 2014. Divergent tissue and sex effects of rapamycin on the proteasome-chaperone network of old mice. Front Mol Neurosci 7: 83.
86. Saci A, Cantley LCT, Carpenter CL. 2011. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 42: 50–61.
87. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141: 290–303.
88. Sans MD, Tashiro M, Vogel NL, Kimball SR, D’Alecy LG, Williams JA. 2006. Leucine activates pancreatic translational machinery in rats and mice through mTOR independently of CCK and insulin. J Nutr 136: 1792–1799.
89. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/ PKB. Mol Cell 22: 159–168.
90. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, et al. 2009. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326: 140–144.
91. Selman C, Partridge L, Withers DJ. 2011. Replication of extended lifespan phenotype in mice with deletion of insulin receptor substrate 1. PLoS ONE 6: e16144.
92. Seto B. 2012. Rapamycin and mTOR: A serendipitous discovery and implications for breast cancer. Clin TransMed 1: 29.
93. Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, Huynh T, Ferron M, Karsenty G, Vellard MC, et al. 2012. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J 31: 1095–1108.
94. Solon-Biet SM, McMahon AC, Ballard JW, Ruohonen K, Wu LE, Cogger VC, Warren A, Huang X, Pichaud N, Melvin RG, et al. 2014. The ratio of macronutrients, not caloric intake, dictates cardiometabolic health, aging, and longevity in ad libitum-fed mice. Cell Metab 19: 418–430.
95. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V. 2010. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer’s disease. PLoS ONE 5: e9979.
96. Steffen KK, MacKay VL, Kerr EO, Tsuchiya M, Hu D, Fox LA, Dang N, Johnston ED, Oakes JA, Tchao BN, et al. 2008. Yeast life span extension by depletion of 60s ribosomal subunits is mediated by Gcn4. Cell 133: 292–302.
97. Syntichaki P, Troulinaki K, Tavernarakis N. 2007. eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans. Nature 445: 922–926.
98. Tao R, Xiong X, Liangpunsakul S, Dong XC. 2014. Sestrin 3 protein enhances hepatic insulin sensitivity by direct activation of the mTORC2-Akt signaling. Diabetes 64: 1211–1223.
99. Tardif S, Ross C, Bergman P, Fernandez E, Javors M, Salmon A, Spross J, Strong R, Richardson A. 2014. Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci 70: 577–587.
100. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. 2012. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485: 109–113.
101. Varga R, Eriksson M, Erdos MR, Olive M, Harten I, Kolodgie F, Capell BC, Cheng J, Faddah D, Perkins S, et al. 2006. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson–Gilford progeria syndrome. Proc Natl Acad Sci 103: 3250–3255.
102. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Muller F. 2003. Genetics: Influence of TOR kinase on lifespan in C. elegans. Nature 426: 620.
103. Vezina C, Kudelski A, Sehgal SN. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. I: Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28: 721–726.
104. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, et al. 2014. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer discovery 4: 546–553.
105. White E, Karp C, Strohecker AM, Guo Y, Mathew R. 2010. Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol 22: 212–217.
106. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, et al. 2012. Rapamycin slows aging in mice. Aging Cell 11: 675–682.
107. Xiao F, Huang Z, Li H, Yu J, Wang C, Chen S, Meng Q, Cheng Y, Gao X, Li J, et al. 2011. Leucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/ S6K1 and AMPK pathways. Diabetes 60: 746–756.
108. Yang SB, Lee HY, Young DM, Tien AC, Rowson-Baldwin A, Shu YY, Jan YN, Jan LY. 2012. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med (Berl) 90: 575–585.
109. Yilmaz OH, Katajisto P, Lamming DW, Gultekin Y, Bauer-Rowe KE, Sengupta S, Birsoy K, Dursun A, Yilmaz VO, Selig M, et al. 2012. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 486: 490–495.
110. Zahr E, Molano RD, Pileggi A, Ichii H, San Jose S, Bocca N, An W, Gonzalez-Quintana J, Fraker C, Ricordi C, et al. 2008. Rapamycin impairs b-cell proliferation in vivo. Transplant Proc 40: 436–437.
111. Zhang C, Cuervo AM. 2008. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med 14: 959–965.
112. Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, Diaz V, Sloane L, Maslin K, Treaster S, et al. 2014. Rapamycin extends life and health in C57BL/6 mice. J Gerontol A Biol Sci Med Sci 69: 119–130.
113. Zid BM, Rogers AN, Katewa SD, Vargas MA, Kolipinski MC, Lu TA, Benzer S, Kapahi P. 2009. 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell 139: 149–160.
114. Zinzalla V, Stracka D, Oppliger W, Hall MN. 2011. Activation of mTORC2 by association with the ribosome. Cell 144: 757–768.